TrialBlood2016

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

Andrzej Jakubowiak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.